USFDAMay 14, 2026, 05:29 PM
Glucotrack Submits IDE to FDA for Implantable CBGM; Targets US Clinical Study 2H 2026
AI Summary
Glucotrack, Inc. announced the submission of its Investigational Device Exemption (IDE) application to the U.S. FDA to initiate a U.S. clinical study for its fully implantable continuous blood glucose monitoring (CBGM) technology, targeting a launch in the second half of 2026. This milestone is supported by positive preclinical and in-vitro data published in peer-reviewed journals, demonstrating long-term sensor stability and accuracy. For Q1 2026, the company reported a reduced net loss of $4.3 million and strengthened its balance sheet by cutting debt and extending its financial runway.
Key Highlights
- Glucotrack submitted an Investigational Device Exemption (IDE) application to the FDA for its fully implantable CBGM technology.
- Company targets U.S. clinical trial launch for its CBGM in the second half of 2026.
- Peer-reviewed data validated 3-year sensor longevity and showed 6.8% MARD in an ovine study.
- Net loss for Q1 2026 decreased to $4.3 million from $6.8 million in Q1 2025.
- Cash and cash equivalents were $3.9 million as of March 31, 2026.
- Reduced outstanding promissory note balance from $3.6 million to approximately $1.6 million.
- Existing cash provides sufficient runway into early Q3 2026.